The latest price of platinib in 2024 published on the entire network

Introduction: Platinib is a RET inhibitor and belongs to the broader anti-cancer drug class of tyrosine kinase inhibitors. Platinib blocks the activity of an abnormal protein called RET fusion protein, which is produced by the body due to changes in the RET gene. In NSCLC cells, the RET fusion protein can lead to uncontrolled cell growth and cancer. By blocking the RET fusion protein, Platinib helps reduce the growth and spread of cancer.

The latest price of Platinib in 2024 announced on the entire website

is currently included in medical insurance. The winning bid price of the drug learned in 2024 is 60,000$ per box, and the price after reimbursement will be cheaper. The price of the generic version of Platinib produced by Lucius Pharmaceuticals is about 3715$-4200$ per box, and the specification of a box is 100mg × 120 tablets.

Platinib drug prices may vary depending on regions, pharmacies and purchase channels. Patients are advised to understand the price before purchasing and purchase a suitable version of Platinib.

Side effects of Platinib

Common side effects of Platinib mainly include high blood pressure, low blood cell count, muscle or joint pain, fatigue, constipation, etc. Serious side effects mainly include fever, chills, cough, shortness of breath, chest pain, severe headache, dizziness, difficulty speaking, abnormal bleeding or bruising, liver problems, etc.

If are not serious, special treatment is generally not required. However, if they last for a long time or are severe, the patient should immediately report any serious or abnormal symptoms to the doctor, and the doctor will carry out targeted treatment based on the specific symptoms of the side effects.

If you have severe eye symptoms, such as sudden vision loss, blurred vision, narrow field of vision, eye pain or swelling, or seeing halos around lights, you need immediate medical treatment.

Drug Precautions

1. Monitor AST/ALT before starting platinib treatment, every 2 weeks in the first 2 months, and then monthly, and according to clinical indications.

2. It may cause serious or even fatal bleeding events.

3. According to the results of animal studies and its mechanism of action, giving it to pregnant women may cause harm to the fetus.

4. Tumor lysis syndrome has been reported in patients treated with Platinib. Patients may be at risk of TLS if their tumors grow rapidly, have high tumor burden, have renal insufficiency or are dehydrated. Monitor at-risk patients closely, consider appropriate precautions, including hydration, and treat as clinically indicated.